You are not authorized to access this page.
Search Within

Barbara Ann Macgregor-Cortelli

Formats
  1. Meeting Abstract (9)
  2. Journal Article (7)
Groups
  1. Nursing (16)
  2. Department of Medicine (15)
  3. Hematologic Malignancies, Division of (14)
  4. Center for Hematologic Malignancies (11)
  5. Lymphoma (11)
  6. Body Imaging Service (5)

More Groups

People
  1. Owen O'connor (15)
  2. Craig Moskowitz (11)
  3. Andrew Zelenetz (10)
  4. David Straus (9)
  5. Paul Hamlin (6)
  6. Carol Portlock (5)

More People

Years
  1. 2007 (2)
  2. 2006 (3)
  3. 2005 (3)
  4. 2004 (3)
  5. 2003 (3)
  6. 2002 (2)
Publications
  1. Blood (6)
  2. British Journal of Haematology (2)
  3. Journal of Clinical Oncology (2)
  4. Clinical Cancer Research (1)
  5. Clinical Oncology (1)
  6. EJC Supplements (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. American Association for Cancer Research (2)
  3. American Society of Clinical Oncology (2)
  4. John Wiley & Sons (2)
  5. Elsevier Science, Inc. (1)
  6. Harborside Press (1)

More Publishers

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P.; Portlock, C.; Moskowitz, C.; Noy, A.; Straus, D.; Dumetrescu, O.; Sarasohn, D.; Neylon, E.; Hamelers, R.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
    Journal Article

    O'Connor, O. A.; Hamlin, P. A.; Portlock, C.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Macgregor-Cortelli, B.; Neylon, E.; Sarasohn, D.; Dumetrescu, O.; more...
    British Journal of Haematology (2007)

    Fulltext@MSK | Save
  • An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib
    Journal Article

    Stubblefield, M. D.; Slovin, S.; Macgregor-Cortelli, B.; Muzzy, J.; Scher, H.; Wright, J.; Esseltine, D.; Schenkein, D.; O'Connor, O. A.
    Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Journal Article

    O'Connor, O. A.; Heaney, M. L.; Schwartz, L.; Richardson, S.; Willim, R.; Macgregor-Cortelli, B.; Curly, T.; Moskowitz, C.; Portlock, C.; Horwitz, S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response?
    Journal Article

    Gerecitano, J.; Goy, A.; Wright, J.; Macgregor-Cortelli, B.; Neylon, E.; Gonen, M.; Esseltine, D.; Boral, A.; Schenkein, D.; Busam, K.; more...
    British Journal of Haematology (2006)

    Fulltext@MSK | Save
  • Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity
    Meeting Abstract

    O'connor, O.; Hamlin, P. A.; Neylon, E.; Moskowitz, C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Cortelli, B.; Zelenetz, A. D.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Journal Article

    O'Connor, O. A.; Wright, J.; Moskowitz, C.; Muzzy, J.; Macgregor-Cortelli, B.; Stubblefield, M.; Straus, D.; Portlock, C.; Hamlin, P.; Choi, E.; more...
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Drug-induced cutaneous vasculitis in patients with non-Hodgkin's lymphoma receiving bortezomib: A possible surrogate marker of response
    Meeting Abstract

    Gerecitano, J.; Goy, A.; Macgregor-Cortelli, B.; Neylon, E.; Wright, J.; Esseltine, D.; Schenkein, D.; Gonen, M.; O'Connor, O. A.
    Blood (2005)

    Fulltext@MSK | Save
  • Integrating flextime with primary nursing in the oncology ambulatory setting: A new model for practice
    Meeting Abstract

    Schmidt, E.; Schaindlin, P.; Dosil-Loiacono, S.; Macgregor-Cortelli, B.
    Oncology Nursing Forum (2004)

    Fulltext@MSK | Save
  • A Multicenter experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked differences in sub-type sensitivity to proteasome inhibition
    Meeting Abstract

    O'connor, O.; Wright, J.; Moskowitz, C.; Macgregor-Cortelli, B.; Straus, D.; Evans, A.; Winter, J.; Koc, O.; Horvath, N.; Blumel, S.; more...
    Blood (2004)

    Fulltext@MSK | Save